{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:31:32Z","timestamp":1789011092098,"version":"build-2803163510"},"reference-count":57,"publisher":"Informa UK Limited","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Cycle"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.4161\/cc.25914","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T20:40:11Z","timestamp":1377117611000},"page":"2829-2838","source":"Crossref","is-referenced-by-count":27,"title":["Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors"],"prefix":"10.1080","volume":"12","author":[{"given":"Caterina","family":"Ieran\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Nicolae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Robey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R2","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"R3","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"R4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"R5","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"R7","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(11)70265-0","article-title":"Mocetinostat for relapsed classical Hodgkin\u2019s lymphoma: an open-label, single-arm, phase 2 trial","volume":"12","author":"Younes","year":"2011","journal-title":"Lancet Oncol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med Chem"},{"key":"R10","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-08-2787","article-title":"Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications","volume":"15","author":"Schrump","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance","volume":"8","author":"Robey","year":"2011","journal-title":"Mol Pharm"},{"key":"R12","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"},{"key":"R13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.18632\/oncotarget.724","article-title":"Superior efficacy of co-treatment with dual PI3K\/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer","volume":"3","author":"Venkannagari","year":"2012","journal-title":"Oncotarget"},{"key":"R14","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/cdd.2012.94","article-title":"BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma","volume":"19","author":"Shao","year":"2012","journal-title":"Cell Death Differ"},{"key":"R15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.18632\/oncotarget.430","article-title":"A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer","volume":"3","author":"Stauber","year":"2012","journal-title":"Oncotarget"},{"key":"R16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","article-title":"Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein","volume":"102","author":"Aron","year":"2003","journal-title":"Blood"},{"key":"R17","doi-asserted-by":"crossref","first-page":"11317","DOI":"10.1073\/pnas.0801868105","article-title":"Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist","volume":"105","author":"Frew","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1038\/sj.onc.1203176","article-title":"Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2\/Bcl-XL, c-Jun, and p21CIP1, but independent of p53","volume":"18","author":"Vrana","year":"1999","journal-title":"Oncogene"},{"key":"R19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1535-7163.MCT-07-2256","article-title":"Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin","volume":"7","author":"Newbold","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R20","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0006-2952(02)01261-3","article-title":"Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo","volume":"64","author":"Sasakawa","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"R21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.leukres.2008.12.013","article-title":"Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines","volume":"33","author":"Hartlapp","year":"2009","journal-title":"Leuk Res"},{"key":"R22","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"R24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.726","article-title":"Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells","volume":"3","author":"Sander","year":"2012","journal-title":"Oncotarget"},{"key":"R25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/ni.2418","article-title":"The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers","volume":"13","author":"Calado","year":"2012","journal-title":"Nat Immunol"},{"key":"R26","doi-asserted-by":"crossref","first-page":"e10941","DOI":"10.1371\/journal.pone.0010941","article-title":"The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo","volume":"5","author":"Lucas","year":"2010","journal-title":"PLoS One"},{"key":"R27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200201270-00021","article-title":"A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease","volume":"73","author":"Sculley","year":"2002","journal-title":"Transplantation"},{"key":"R28","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.onc.1202059","article-title":"Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression","volume":"17","author":"Wang","year":"1998","journal-title":"Oncogene"},{"key":"R29","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/jnci\/94.7.504","article-title":"Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228","volume":"94","author":"Yu","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/jpet.105.083956","article-title":"Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines","volume":"314","author":"Xiao","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1078-0432.CCR-05-1423","article-title":"Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)","volume":"12","author":"Robey","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R33","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1271\/bbb.58.1579","article-title":"Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells","volume":"58","author":"Ueda","year":"1994","journal-title":"Biosci Biotechnol Biochem"},{"key":"R34","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bcp.2011.02.010","article-title":"Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt\u2019s and Hodgkin\u2019s lymphomas","volume":"81","author":"Mori","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"R35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/labinvest.2009.106","article-title":"Analysis of Aurora B kinase in non-Hodgkin lymphoma","volume":"89","author":"Ikezoe","year":"2009","journal-title":"Lab Invest"},{"key":"R36","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.25218","article-title":"Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance","volume":"127","author":"Shao","year":"2010","journal-title":"Int J Cancer"},{"key":"R37","first-page":"696","article-title":"Bax is frequently compromised in Burkitt\u2019s lymphomas with irreversible resistance to Fas-induced apoptosis","volume":"59","author":"Guti\u00e9rrez","year":"1999","journal-title":"Cancer Res"},{"key":"R38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2009.08.011","article-title":"Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways","volume":"79","author":"Li","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"R39","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.1059108","article-title":"Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death","volume":"292","author":"Wei","year":"2001","journal-title":"Science"},{"key":"R40","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/onc.2011.497","article-title":"Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak","volume":"31","author":"Wang","year":"2012","journal-title":"Oncogene"},{"key":"R41","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.275.5302.967","article-title":"Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype","volume":"275","author":"Rampino","year":"1997","journal-title":"Science"},{"key":"R42","first-page":"1071","article-title":"The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium","volume":"4","author":"Ouyang","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.onc.1201944","article-title":"Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability","volume":"17","author":"Percesepe","year":"1998","journal-title":"Oncogene"},{"key":"R44","first-page":"4095","article-title":"Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability","volume":"62","author":"Vassileva","year":"2002","journal-title":"Cancer Res"},{"key":"R45","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/sj.onc.1201704","article-title":"BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability","volume":"16","author":"Brimmell","year":"1998","journal-title":"Oncogene"},{"key":"R46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archsurg.2009.42","article-title":"Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma","volume":"144","author":"Corso","year":"2009","journal-title":"Arch Surg"},{"key":"R47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/egh.11.25","article-title":"Microsatellite instability in the management of colorectal cancer","volume":"5","author":"Pino","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R48","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1073\/pnas.190210897","article-title":"Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution","volume":"97","author":"Ionov","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R49","first-page":"4471","article-title":"Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma","volume":"55","author":"Krajewski","year":"1995","journal-title":"Cancer Res"},{"key":"R50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10620-010-1280-8","article-title":"Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy","volume":"56","author":"Jeong","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R51","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-06-3063","article-title":"Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy","volume":"13","author":"Kang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R52","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.bjc.6600765","article-title":"Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder","volume":"88","author":"Hussain","year":"2003","journal-title":"Br J Cancer"},{"key":"R53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-2141.2000.02315.x","article-title":"High bax expression is a good prognostic indicator in acute myeloid leukaemia","volume":"111","author":"Ong","year":"2000","journal-title":"Br J Haematol"},{"key":"R54","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","article-title":"Epidemiology: clues to the pathogenesis of Burkitt lymphoma","volume":"156","author":"Magrath","year":"2012","journal-title":"Br J Haematol"},{"key":"R55","doi-asserted-by":"crossref","first-page":"130680","DOI":"10.1155\/2012\/130680","article-title":"Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and CNS prophylaxis","volume":"2012","author":"Magrath","year":"2012","journal-title":"Adv Hematol"},{"key":"R56","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.290.5493.989","article-title":"Role of BAX in the apoptotic response to anticancer agents","volume":"290","author":"Zhang","year":"2000","journal-title":"Science"}],"container-title":["Cell Cycle"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.4161\/cc.25914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T15:56:15Z","timestamp":1563724575000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/cc.25914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":57,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2014,10,28]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.4161\/cc.25914"],"URL":"https:\/\/doi.org\/10.4161\/cc.25914","relation":{},"ISSN":["1538-4101","1551-4005"],"issn-type":[{"value":"1538-4101","type":"print"},{"value":"1551-4005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}